Blueprint Medicines Corp BPMC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BPMC is a good fit for your portfolio.
News
-
Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
-
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Blueprint Medicines Corporation and Encourages Investors to Contact the Firm
-
Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting
-
BPMC INVESTOR ALERT: Andrews & Springer LLC Investigates Blueprint Medicines Corporation
-
BPMC Alert: The Law Firm of Andrews & Springer LLC Is Investigating Blueprint Medicines Corporation For Potential Securities Violations and Breaches of Fiduciary Duty
-
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
-
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
-
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
Trading Information
- Previous Close Price
- $106.36
- Day Range
- $104.30–108.53
- 52-Week Range
- $43.89–111.02
- Bid/Ask
- $97.00 / $107.60
- Market Cap
- $6.61 Bil
- Volume/Avg
- 631,490 / 685,533
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 21.91
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 655
Comparables
Valuation
Metric
|
BPMC
|
VRDN
|
VTYX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 20.26 | 2.00 | 1.10 |
Price/Sales | 21.91 | 2,057.71 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
BPMC
VRDN
VTYX
Financial Strength
Metric
|
BPMC
|
VRDN
|
VTYX
|
---|---|---|---|
Quick Ratio | 3.43 | 17.93 | 20.82 |
Current Ratio | 3.76 | 18.26 | 22.00 |
Interest Coverage | −14.25 | −137.76 | — |
Quick Ratio
BPMC
VRDN
VTYX
Profitability
Metric
|
BPMC
|
VRDN
|
VTYX
|
---|---|---|---|
Return on Assets (Normalized) | −31.84% | −42.76% | −48.02% |
Return on Equity (Normalized) | −128.33% | −82.42% | −51.90% |
Return on Invested Capital (Normalized) | −59.15% | −50.70% | −55.64% |
Return on Assets
BPMC
VRDN
VTYX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ccdrgctj | Dmm | $590.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qlhckqyn | Chkkdc | $113.8 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Smjtnqpn | Gtwdnzf | $106.5 Bil | |
MRNA
| Moderna Inc | Vwtsflmv | Hmzlx | $58.7 Bil | |
BNTX
| BioNTech SE ADR | Wlpxpyzzy | Lfxhv | $23.8 Bil | |
ARGX
| argenx SE ADR | Hkvzxhlpb | Krnd | $21.6 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Cbfwtcdrz | Zbfwgs | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fzytpjt | Wqmyzns | $14.1 Bil | |
INCY
| Incyte Corp | Qrchqwdx | Sxbbsp | $12.9 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ypgvkwqgg | Cqczgrn | $12.4 Bil |